Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have earned an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $29.50.

Several research firms have recently weighed in on RCUS. Morgan Stanley decreased their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Bank of America decreased their price target on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, February 19th. HC Wainwright lowered their price objective on Arcus Biosciences from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Finally, Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a research report on Thursday, November 7th.

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $10.16 on Tuesday. The stock has a market capitalization of $1.07 billion, a PE ratio of -3.23 and a beta of 0.84. The business’s 50 day simple moving average is $13.79 and its 200 day simple moving average is $15.54. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. Arcus Biosciences has a one year low of $10.12 and a one year high of $20.31.

Insiders Place Their Bets

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now owns 60,138 shares in the company, valued at approximately $902,070. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. R Squared Ltd acquired a new stake in shares of Arcus Biosciences in the 4th quarter worth about $26,000. Point72 Hong Kong Ltd bought a new stake in Arcus Biosciences during the 3rd quarter worth approximately $47,000. Lazard Asset Management LLC raised its stake in shares of Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after purchasing an additional 6,078 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after purchasing an additional 6,615 shares in the last quarter. Finally, Quest Partners LLC lifted its holdings in shares of Arcus Biosciences by 40,904.3% in the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares in the last quarter. 92.89% of the stock is owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.